AL類澱粉沉積症：市場展望、流行病學、競爭格局、市場預測報告（2025-2035年）

市場概覽

• 德國AL類澱粉沉積症市場預計將從2025年的5,000萬美元成長到2035年的1.1億美元。
• 推動市場成長的因素如下：
• 擴大新型漿細胞標靶治療和聯合療法的應用。
• 提高疾病認知並擴大診斷能力
• 未來的成長取決於能夠促進器官恢復和緩解疾病，同時實現持續血液學反應的治療方法。

AL類澱粉沉積症變性概述

AL類澱粉沉積症是一種危及生命的漿細胞疾病，其特徵是克隆性免疫球蛋白輕鏈異常折疊成澱粉樣原纖維，沉積於器官中，導致進行性功能障礙。心臟和腎臟病變可導致限制性心肌病、心臟衰竭和腎病變蛋白尿。巨舌症、紫斑和神經病變也可能發生。診斷需要進行組織切片檢查，並進行屈光試驗和剛果紅染色分型，以及血清和尿液免疫固定和遊離輕鏈測定。治療以快速改善血液學反應為首要目標，通常採用daratumumab合併bortezomib、cyclophosphamide和dexamethasone。自體幹細胞移植僅適用於合格的患者。

主要亮點

• 在美國，AL類澱粉沉積症新發病例數預計將從2025年的5,209例增加到2035年的5,602例。
• AL類澱粉沉積症是一種罕見的進行性全身性疾病，其特徵是嚴重的器官功能障礙和壽命縮短。
• 由於該疾病的症狀多種多樣且不特異性，因此診斷延誤仍然是一項重大挑戰。
• 儘管近年來治療方法取得了進展，但對於能夠改善器官反應和長期存活率的治療方法，仍存在巨大的未滿足需求。

格式化和更新訊息

• 詳細報告（PDF）
• 市場預測模型（基於MicrosoftExcel）
• 流行病學資料（MS Excel，互動式工具）
• 高層洞察（PPT簡報）
• 其他功能：定期更新、自訂和顧問支援。
• 根據 Thelansis 的政策，確保所有最新更新在發布前都反映在報告內容和市場模型中。

主要問題

• 如何最佳化 G8 市場（美國、歐盟 5 國、日本、中國）的藥物開發與生命週期管理策略？
• 從發病率、盛行率、人群組成以及接受藥物治療的患者人數來看，患者數量分別是多少？
• 未來十年市場收入和病患佔有率的預測是多少？
• 哪些因素對市場趨勢影響最大？
• 受訪專家對目前和新興的治療方法有何看法？
• 哪款在研發線產品最有前景？其上市潛力及未來市場定位如何？
• 主要未被滿足的需求是什麼？ KOL 對目標受眾有何期望？
• 為確保藥物獲得批准並順利進入市場，必須滿足哪些關鍵的監管和支付方要求？

目標國家

• G8
  • 美國
  • EU5
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 英國
  • 日本
  • 中國

主要企業

• Alexion Pharmaceuticals, Inc.
• Nexcella Inc.
• Lantheus Germany GmbH
• Janssen Research &Development, LLC
• Nanjing IASO Biotechnology Co., Ltd.
• Gracell Biotechnologies（Shanghai）Co., Ltd.
• AbbVie

目錄

第1章 主要調查結果及分析師說明

• 主要趨勢：市場概況、SWOT分析、商業性利益與風險等。

第2章 疾病背景

• 疾病定義、分類、病因和病理生理學、藥物標靶等。

第3章 流行病學

• 重點
• 發病率/盛行率
• 已確診並接受藥物治療的患者人數
• 合併症
• 其他相關患者群

第4章 市場規模及預測

• 重點
• 市場促進因素與限制因素
• 依藥物類別分類的趨勢
• 各國具體趨勢

第5章 競爭情勢

• 目前的治療方法
• 重點
• 診斷和治療過程/演算法
• 主要治療方法概述及關鍵意見領袖見解
• 新興治療方法
• 重點
• 值得關注的後期新治療方法 - 概述、市場上市預期及關鍵意見領袖見解
• 值得關注的早期研發管線

第6章 未滿足的需求與TPP分析

• 主要未滿足的需求以及透過新興治療方法實現的未來可能性
• TPP分析與KOL展望

第7章 監理與償付環境

第8章 附錄

AL Amyloidosis Market Outlook

Thelansis's "AL Amyloidosis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential AL Amyloidosis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

AL Amyloidosis Overview

AL amyloidosis is a life-threatening plasma cell disorder in which clonal immunoglobulin light chains misfold into amyloid fibrils that deposit in organs and cause progressive dysfunction. Cardiac and renal involvement produce restrictive cardiomyopathy, heart failure, and nephrotic proteinuria; macroglossia, purpura, and neuropathy may occur. Diagnosis requires tissue biopsy with Congo red birefringence and typing plus serum and urine immunofixation and free light chain assays. Treatment prioritizes rapid hematologic response, typically daratumumab with bortezomib, cyclophosphamide and dexamethasone; autologous stem cell transplant is reserved for selected fit patients.

Key Highlights

• In the United States, incident AL Amyloidosis cases are projected to increase from 5,209 in 2025 to 5,602 by 2035.
• AL Amyloidosis is a rare and progressive systemic disorder associated with significant organ dysfunction and reduced survival.
• Delayed diagnosis remains a major challenge due to the heterogeneous and non-specific nature of disease presentation.
• Despite recent therapeutic advances, substantial unmet need persists for treatments capable of improving organ responses and long-term survival.

Market Overview

• The Germany AL Amyloidosis market is projected to grow from $50M in 2025 to $110M by 2035.
• Market growth is driven by:
• Increasing adoption of novel plasma cell-directed therapies and combination treatment regimens
• Improved disease recognition and expanding diagnostic capabilities
• Future growth will depend on therapies capable of achieving durable hematologic responses while promoting organ recovery and disease modification.

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Alexion Pharmaceuticals, Inc.
• Nexcella Inc.
• Lantheus Germany GmbH
• Janssen Research & Development, LLC
• Nanjing IASO Biotechnology Co., Ltd.
• Gracell Biotechnologies (Shanghai) Co., Ltd.
• AbbVie

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
• Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)